Академический Документы
Профессиональный Документы
Культура Документы
ST-ELEVADO
Alexander Montesinos
Cardenas
Applying Classification of
Recommendations and Level of Evidence
Class I Class IIa Class IIb Class III
Benefit >>> Risk Benefit >> Risk Benefit Risk Risk Benefit
Additional studies with Additional studies with No additional studies
focused objectives broad objectives needed
needed needed; Additional
registry data would be Procedure/Treatment
Procedure/ Treatment IT IS REASONABLE helpful should NOT be
SHOULD be to perform performed/administered
performed/ procedure/administer Procedure/Treatment SINCE IT IS NOT
administered treatment MAY BE CONSIDERED HELPFUL AND MAY BE
HARMFUL
Benefit >>> Risk Benefit >> Risk Benefit Risk Risk Benefit
Additional studies with Additional studies with No additional studies
focused objectives broad objectives needed
needed needed; Additional
registry data would be Procedure/Treatment
Procedure/ IT IS REASONABLE to helpful should NOT be
Treatment SHOULD perform performed/administered
be performed/ procedure/administer Procedure/Treatment SINCE IT IS NOT
administered treatment MAY BE CONSIDERED HELPFUL AND MAY
BE HARMFUL
Level B: Recommendation based on evidence from a single randomized trial or non-randomized studies
Limited (2-3) population risk strata
evaluated
Level C: Recommendation based on expert opinion, case studies, or standard-of-care
Very limited (1-2) population risk strata evaluated
SINDROME CORONARIO AGUDO
OBJETIVOS:
Disminuir el rea de necrosis
Prevencin de efectos adversos
Desfibrilacin rpida ante FV
Diagnostico temprano
Tratamiento precoz
Estabilizacin del SCA
complicado
ACS: Initial Diagnostic Strategies
Definite ACS
Noncardiac Diagnosis Chronic Stable Possible ACS
Angina
No ST-Elevation ST-Elevation
Treatment as ACC/AHA Chronic
indicated by Stable Angina
alternative diagnosis Guidelines
ST and/or T wave changes
Nondiagnostic ECG
Normal initial serum Ongoing pain
cardiac biomarkers
Positive cardiac
biomarkers
Observe Hemodynamic
abnormalities
12 h from symptom onset
Evaluate for
reperfusion therapy
SINTOMATOLOGIA ASOCIADA
Disnea
Diaforesis
Nauseas y vmitos
Hipotensin Arterial.
ASINTOMATICOS : 25%
CRITERIOS DIAGNOSTICOS
II. ENZIMATICO
CPK-MB 3 - 12 24 2-3
Mioglobina 1-4 6-7 1
Troponina 3-6 12 - 24 7 - 10
TGO 6 - 12 18 - 36 3-4
DHL 12 72 - 96 8 - 14
Examen Fisico breve en emergencia
Observacin
Seriar: ECG y enzimas Tto antiisquemia MONA
Test de Esfuerzo MONA Decidir Tto Reperfusin
Otros Dg.. Trombolisis (30 min.)
Angioplasta 1ria (90 mi
Normal SCA
Tto antiisquemia
Unidad Critica B bloqueadores
Alta (UCE/UCI/UDT) Nitratos
(8-12h) Analgesia
Manejo ST elevado
Aspirina
B bloqueador
> 12 h
< 12 h
Tto Antiisquemia
Trombolisis Considerar
Nitratos
tto Reperfusi
Inhibidores ECA
PTCA Anticoagulacin
CABG
CLASIFICACION DE KILLIP-KIMBALL
I
no ICC 30% 5%
II
moderada
ICC rales bilat
S3 40% 15-20%
III
franco EAP 10% 40%
IV
Shock
Cardiognico 20% 80%
TIMI Risk Score for ST
Elevation MI
Palm Pilot
application
available at:
www.timi.org
CLASE II a
Elevacin ST y > 75 aos
CLASE II b
Elevacin ST y tiempo de inicio de 12 a 24 horas
PAS > 180 mm Hg y/o PAD > 110 mmHg asociada a un alto
riesgo de IMA
Clase III
Elevacin ST, tiempo de inicio > 24 horas, con dolor isqumico
resuelto
Depresin del segmento ST solamente
AGENTES TROMBOLITICOS
Dosis
Tiempo adm
Forma adm.
Tiempo 1/2
Antignico
Alergia
Deplecin
Fibrinogeno
Flujo TIMI3
Mortalidad Streptokinasa Anisteplase Alteplase
Costo Reteplase
Adicional
TERAPIA DE REPERFUSION
Heparina : Infusin -- SC
Heparina de bajo peso molecular
Aspirina 160 - 325 mg/dia
Warfarina (INR 2-3)
Acute MI: ASA benefit
ISIS-2: 17, 187 patients: Acute MI
23%
mortality
reduction 42%
mortality
reduction
Protocolo Para el Uso de Heparina En IMA (Hirish)
<50 5,000 0 +4
50-59 0 0 +3
60-85 0 0 0
86-95 0 0 -2
96-120 0 30 -2
> 120 0 60 -4
Uso de Beta Bloqueadores en el IMA
Atenolol 5 - 10 mg
Uso de Beta Bloqueadores en el IMA
Contraindicaciones
Beneficios: Precauciones :